Table 1 Pretreatment patient characteristics

Number of patients

149

39

110

Categorical variables

 Sex (% female)

128 (86 %)

34 (87 %)

94 (85 %)

0.7937

 RF status (% positive)

126 (85 %)

21 (54 %)

105(95 %)

<0.0001

 ACPA status (% positive)

97 (65 %)

20 (67 %)^a

78 (98 %)^b

<0.0001

 14-3-3η status (% positive)

110 (74 %)

0 (0 %)

110 (100 %)

<0.0001

 Concomitant use of MTX (%)

117 (79 %)

34 (87 %)

83 (76 %)

0.1733

Continuous variables

 Age (yr)^c

57.3 (14.7)

54.6 (16.1)

58.2 (14.1)

0.1924

 RA duration (mo)

51 (9–150)

34 (9–132)

55 (11–159)

0.3791

 MTX dose (mg/wk)

8.0 (5.0–10.0)

8.0 (6.0–10.0)

8.0 (1.5–10.0)

0.456

 DAS28-ESR

5.35(4.40–6.45)

4.77 (4.10–5.86)

5.62 (4.64–6.57)

0.0101

 HAQ^d

1.07 (0.60–1.88)

1.00 (0.47–1.88)

1.13 (0.63–1.85)

0.7328

 CDAI

22.2 (14.0–33.5)

16.0 (11.5–27.0)

24.7 (16.2–36.3)

0.015

 SDAI

24.3 (14.3–37.4)

18.8 (11.7–32.7)

26.8 (16.7–38.6)

0.0238

 TJC28

7.0 (4.0–13.5)

5.0 (2.0–12.0)

7.0 (4.0–14.0)

0.0327

 SJC28

6.0 (2.0–9.0)

4.0 (2.0–9.0)

6.5 (2.8–10.0)

0.0466

 SHS

26.5 (4.5–90.8)

14.0 (3.0–88.5)

31.3 (6.9–99.9)

0.1185

 JSN score^e

18.0 (3.0–45.5)

9.0 (1.5–42.5)

19.8 (4.1–47.4)^f

0.11

 Erosion score^e

10.5 (2.0–45.5)

5.0 (2.0–40.5)

12.8 (2.5–53.0)^f

0.108

 ESR

44.0 (21.5–72.5)

35.0 (17.0–58.0)

47.5 (22.8–80.0)

0.0482

 CRP (mg/dl)

0.83(0.23–3.13)

0.69 (0.20–2.70)

0.99 (0.26–3.44)

0.3769

 RF

60.4 (27.4–171.8)

15.5 (5.8–43.2)

84.5 (41.9–242.1)

<0.0001

 ACPA

100.0 (27.4–100)

16.9 (1.9–100)^a

100.0 (52.0–100)^b

0.0002

 14-3-3η (ng/ml)

0.70 (0.17–5.96)

0.10 (0.04–0.13)

1.70 (0.49–11.0)

<0.0001